Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry
Launched by M.D. ANDERSON CANCER CENTER · Feb 17, 2025
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The "Blastt Registry" trial is studying how effective a specific treatment called robotic bronchoscopy is for patients with small lung tumors. This treatment is a minimally invasive procedure that uses a robot to help doctors remove or destroy tumors located in the outer parts of the lungs. The goal of the trial is to collect and analyze information from patients at MD Anderson who have lung cancer or tumors that have spread to the lungs, which will help improve understanding and treatment options for these conditions.
To be eligible for this trial, participants need to be patients at MD Anderson who have a record with the hospital and have peripheral lung tumors that are being treated with the robotic bronchoscopy method. However, if a patient's procedure was stopped for technical reasons and not completed, they would not be included in this study. Since the trial is not yet recruiting participants, those interested will need to wait for it to start. If you qualify and choose to participate, you can expect to contribute to important research that may help future patients with similar conditions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • MD Anderson participants (defined as those with an MD Anderson Medical Record Number) with peripheral lung tumors (primary or metastatic) that have been or will be ablated via robotic bronchoscopy.
- Exclusion Criteria:
- • Patient with planned bronchoscopic ablations of peripheral lung tumors that were aborted for technical reasons (ablation was not completed).
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Roberto F Casal, MD
Principal Investigator
Prinicipal Investigator
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported